following a full submission
aflibercept (Eylea®) is accepted for restricted use within NHS Scotland.
Indication under review: For adults for the treatment of visual impairment due to diabetic macular oedema (DMO).
SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.
Intravitreal aflibercept significantly improved BCVA at 52 weeks compared with laser photocoagulation in two phase III, double-masked studies.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHS Scotland.
Download detailed advice184KB (PDF)
Medicine details
- Medicine name:
- aflibercept (Eylea)
- SMC ID:
- 1003/14
- Indication:
- Treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 November 2014